Company Monitoring Page for Amgen

job ratings (see below graph) for Amgen

latest headlines for company on cafepharma

Is Amgen a Buffett Stock?
Motley Fool
Fri, 12/30/11 - 01:28 pm
Tags:
Amgen, Warren Buffett
Amgen: Xgeva panel review scheduled for February
Yahoo/AP
Thu, 12/29/11 - 10:35 pm
Tags:
Amgen, Xgeva, advisory panel, FDA, prostate cancer
Pharma winners of 2011 could keep surging next year
Investorplace
Wed, 12/28/11 - 12:08 pm
Tags:
Amgen, Biogen Idec, Celgene, Gilead, Pharmasset, Alexion, Regeneron
Recent Performance Review Of 5 Large Cap Biotech Equities
Seeking Alpha
Tue, 12/27/11 - 12:36 pm
Tags:
Alexion, Amgen, Biogen Idec, Celgene, Gilead, Merck, Pfizer
Biotech Stock Mailbag: Most Important Events for 2012
TheStreet.com
Fri, 12/23/11 - 08:56 am
Tags:
Oncothyreon, Keryx, Vical, Aeterna Zentaris, Eli Lilly, JNJ, Elan, Celgene, Pfizer, Gilead, Pharmasset, Threshold Pharmaceuticals, Celldex, Amgen, BioVex, Aveo Pharmaceutical, Amylin, Alkermes, Vertex, Cell Therapeutics, Amarin, ONYX Pharmaceuticals, Vivus
Big Pharma buybacks, spinoffs cater to investors
Fierce Pharma
Fri, 12/23/11 - 08:50 am
Tags:
spin-offs, stock buybacks, investors, Pfizer, GSK, Abbott Laboratories, AstraZeneca, Amgen, Teva Pharmaceuticals, Merck
4 Biotech Stocks With Consistently Rising EPS
Seeking Alpha
Thu, 12/22/11 - 09:16 am
Tags:
Amgen, Biogen Idec, Gilead, Illumina
10 Biotech Stock Predictions for 2012
TheStreet.com
Tue, 12/20/11 - 11:13 am
Tags:
Amgen, FDA, Oncothyreon, Merck KGaA, Vical, GSK, Seattle Genetics, M&A, Celgene, Biomarin, Amag Pharmaceuticals, Momenta, ONYX Pharmaceuticals, Cell Therapeutics, Roche, Aeterna Zentaris, Arena Pharmaceuticals, Vertex, Spectrum Pharmaceuticals
Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars
Yahoo
Mon, 12/19/11 - 04:04 pm
Tags:
Amgen, Watson, biosimilars, cancer, oncology
Amgen rises after announcing retirement of CEO
Yahoo/AP
Sat, 12/17/11 - 11:27 am
Tags:
Amgen, Kevin Sharer
Amgen CEO to Retire
Barron's
Thu, 12/15/11 - 07:12 pm
Tags:
Amgen, Kevin Sharer, Pharma CEOs
2012 Preview: Cancer Immunotherapy Catalysts
Seeking Alpha
Thu, 12/15/11 - 12:08 pm
Tags:
cancer, Antigenics, Amgen, Bristol-Myers Squibb, Celgene, Dendreon, Generex, Merck KGaA, GSK, Idera Pharmaceuticals, NewLink Genetics, Novartis, Roche, Oncothyreon, Transgene, Vical
Amgen More Undervalued Than Johnson & Johnson
Seeking Alpha
Sun, 12/11/11 - 02:45 pm
Tags:
Amgen, JNJ
20 Biotech Stocks That Hedge Funds Are Selling
Seeking Alpha
Sun, 12/11/11 - 02:40 pm
Tags:
Nabi, Pacific Biosciences, Dendreon, Momenta, Enzon, Acorda Therapeutics, ShangPharma, Charles River Laboratories, Sangamo BioSciences, BioSpecifics Technologies, Jazz Pharmaceuticals, Amgen, Sinovac Biotech, ViroPharma, Vanda, Insmed, Transcept, Cadence Pharmaceuticals, PDL Biopharma, Chelsea Therapeutics
Amgen expects to acquire 83.3M shares in buyback
Yahoo/AP
Thu, 12/8/11 - 11:25 am
Tags:
stock buyback, Amgen
Affymax Jumps Most in 16 Months on FDA Review of Anemia Drug
Bloomberg
Mon, 12/5/11 - 01:34 pm
Tags:
Affymax, FDA, anemia, chronic kidney disease, JNJ, Amgen, peginesatide
December Catalysts for Drug and Biotech Stocks
Minyanville
Sat, 12/3/11 - 11:11 am
Tags:
Pfizer, Aveo Pharmaceutical, Affymax, Amgen, Antares Pharma, Celgene, ONYX Pharmaceuticals, Seattle Genetics, Micromet, YM BioSciences, Regeneron, BioSante
5 Risky Biotechs With Serious Profit Potential
Seeking Alpha
Tue, 11/29/11 - 01:37 pm
Tags:
Amgen, Gilead, Spectrum Pharmaceuticals, InterMune, ViroPharma
22 Hot Drugs Facing FDA Approval in 2012
TheStreet.com
Tue, 11/29/11 - 09:09 am
Tags:
Amarin, AMR101, Ironwood, linaclotide, Merck, Ariad, ridaforolimus, Vivus, Qnexa, Avanafil, Amgen, Xgeva, Cell Therapeutics, pixantrone, Kalydeco, Vertex, ONYX Pharmaceuticals, Carfilzomib, Pfizer, Bristol-Myers Squibb, Eliquis, Chelsea Therapeutics, Northera, Levadex, MAP Pharmaceuticals, Roche, Curis, vismodegib, Biogen Idec, Elan, Tysabri, Amylin, Bydureon, Dapagliflozin, Uplypso, Protalix BioTherapeutics, Teva Pharmaceuticals, BioSante, Bio-T-Gel, Corlux, Corcept Therapeutics, Discovery Labs, Surfaxin
New Patent Could Be Worth $6 A Share To Amgen
Forbes
Mon, 11/28/11 - 09:55 am
Tags:
Amgen, patents, Enbrel, rheumatoid arthritis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.